Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  11:36 2022-12-01 am EST
1.585 EUR   -0.31%
11/23Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022
CI
11/23Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
11/14Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biofrontera AG Extends Appointment of Management Board Member Paul B÷ckmann

08/19/2022 | 01:50pm EST

Biofrontera AG announces that the Supervisory Board decided in its meeting on August 19, 2022, to extend the appointment of Mr. Paul Böckmann as member of the Management Board until September 30, 2022. Mr. Paul Böckmann will continue to be available to the company in an advisory capacity until the end of October.


ę S&P Capital IQ 2022
All news about BIOFRONTERA AG
11/23Biofrontera AG Continues to Adhere to Its Forecast for Fiscal Year 2022
CI
11/23Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
11/14Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
10/31Biofrontera Says It Has Agreed to Buy Biofrontera AG Options
MT
10/28BIOFRONTERA AG : RIGHTS ISSUE: 1 new share @ 1 EUR for 8 existing shares
FA
10/24Biofrontera Appoints Fred Leffler as CFO
MT
10/14Biofrontera Adopts Shareholder Rights Plan
MT
10/05Biofrontera Reports Preliminary Q3 Product Revenue -- Stock Down 7% After-Hours
MT
09/06Biofrontera Obtains Notice of Allowance for US Patent Related to Nanoemulsion Technolog..
MT
08/25Biofrontera AG Appoints Prof. Dr. Karin Lergenmüller to the Supervisory Board
CI
More news
Financials
Sales 2022 26,2 M 27,0 M 27,0 M
Net income 2022 -38,1 M -39,3 M -39,3 M
Net Debt 2022 - - -
P/E ratio 2022 -2,65x
Yield 2022 -
Capitalization 90,2 M 93,0 M 93,0 M
Capi. / Sales 2022 3,44x
Capi. / Sales 2023 2,96x
Nbr of Employees 102
Free-Float 49,7%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,59 €
Average target price 2,80 €
Spread / Average Target 76,1%
EPS Revisions
Managers and Directors
Maria del Pilar de la Huerta Martinez Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors